Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.77 |
| ▸ | RECQL | P46063 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 4/20 | 0.74 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.74 |
| ▸ | TP53 | P04637 | 3/20 | 0.74 |
| ▸ | TSHR | P16473 | 3/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.74 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.74 |
| ▸ | THPO | P40225 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.71 |
| ▸ | HRH1 | P35367 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL10496225 | 0.95 | MEN1 (0.71) | MEN1KMT2ACYP2C19RECQLMAPT | |
| SCHEMBL5421345 | 0.93 | MEN1 (0.69) | MEN1KMT2ACYP2C19RECQLMAPT | |
| SCHEMBL5421346 | 0.93 | MEN1 (0.69) | MEN1KMT2ACYP2C19RECQLMAPT | |
| SCHEMBL2351087 | 0.93 | MEN1 (0.80) | MEN1KMT2ACYP2C19RECQLMAPT | |
| SCHEMBL17891477 | 0.93 | MEN1 (0.85) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Hydrochloric Acid SCHEMBL10491648 | 0.92 | MEN1 (0.67) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Butyryl-Carnitine SCHEMBL288391 | 0.91 | MEN1 (0.78) | MEN1KMT2ACYP2C19RECQLMAPT | |
| SCHEMBL17891458 | 0.91 | MEN1 (0.88) | MEN1KMT2ACYP2C19RECQLMAPT | |
| SCHEMBL17891452 | 0.91 | MEN1 (0.88) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Butyryl-Carnitine SCHEMBL886918 | 0.91 | MEN1 (0.78) | MEN1KMT2ACYP2C19RECQLMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000659-A1 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH INC (US) | 2026-01-01 | — | — | US | claimed |
| CN-118489060-A | Compositions and methods for diagnosing and treating chronic kidney disease | 雀巢产品有限公司 | 2024-08-13 | — | — | CN | claimed |
| CN-118055773-A | Lipopeptides inhibitors of interleukin-23 receptor | 詹森生物科技公司 | 2024-05-17 | — | — | CN | claimed |
| CN-112885455-B | Heart failure typing model and kit | 复旦大学附属中山医院 | 2024-02-27 | — | — | CN | claimed |
| CN-109563127-B | Compounds, agents and uses thereof | 麦特博隆股份有限公司 | 2024-01-05 | — | — | CN | claimed |
| CN-114026427-B | Marker for diagnosing kidney disease and diagnostic method | 深圳市中医院 | 2023-11-17 | — | — | CN | claimed |
| CN-114026427-A | Marker for diagnosing renal disease and diagnostic method | 深圳市中医院 | 2022-02-08 | — | — | CN | claimed |
| CN-111406216-A | Compounds, reagents and uses thereof | 麦特博隆股份有限公司 | 2020-07-10 | — | — | CN | claimed |
| EP-2997366-A1 | BIOMARKERS RELATED TO KIDNEY FUNCTION AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2016-03-23 | — | — | EP | claimed |
| CN-104364658-A | Methods for diagnosing chronic valvular disease | NESTEC SA | 2015-02-18 | — | — | CN | claimed |
| CN-103278579-B | Plasma metabolism micromolecular marker related to human intestinal canal aganglionosis and application of plasma metabolism micromolecular marker | XIA YANKAI | 2015-02-11 | — | — | CN | claimed |
| WO-2014186311-A1 | BIOMARKERS RELATED TO KIDNEY FUNCTION AND METHODS USING THE SAME | METABOLON, INC. (US) | 2014-11-20 | — | — | WO | claimed |
| CN-103278579-A | Plasma metabolism micromolecular marker related to human intestinal canal aganglionosis and application of plasma metabolism micromolecular marker | XIA YANKAI | 2013-09-04 | — | — | CN | claimed |
| CN-103229052-A | Biomarkers for prostate cancer and methods of use thereof | METABOLON INC | 2013-07-31 | — | — | CN | claimed |
| US-20260000659-A1 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH INC (US) | 2026-01-01 | — | — | US | disclosed |
| CN-113871008-B | Predictive model for early diagnosis of lung cancer and related products and application thereof | 大连医科大学附属第二医院 | 2024-09-10 | — | — | CN | disclosed |
| CN-118489060-A | Compositions and methods for diagnosing and treating chronic kidney disease | 雀巢产品有限公司 | 2024-08-13 | — | — | CN | disclosed |
| EP-1299011-A2 | COMPOSITION FOR THE TREATMENT OF MIGRAINE | N.V. Nutricia (NL) | 2003-04-09 | — | — | EP | disclosed |
| US-6465517-B1 | TAURINE, COENZYME Q10 AND ADDITIONALLY CREATINE, L-CARNITINE, CERTAIN VITAMINS AND MINERALS, CARBOHYDRATES, PROTEINS, FATS AND HERBAL EXTRACTS | N.V. NUTRICIA (NL) | 2002-10-15 | — | — | US | disclosed |
| WO-2002003815-A2 | COMPOSITION FOR THE TREATMENT OF MIGRAINE | N.V. NUTRICIA (NL) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000659-A1 | LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL36G, IL15RA | MEN1 4732/4885KMT2A 3239/4885CYP2C19 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.